Defunct Company
Total Trials
10
As Lead Sponsor
8
As Collaborator
2
Total Enrollment
1,283
NCT02974010
Sequential Therapy for the Treatment of Severe Bipolar Depression.
Phase: Phase 2
Role: Lead Sponsor
Start: Jan 15, 2018
Completion: Nov 20, 2019
NCT03402152
NRX101 Glx Biomarker Validation Study
Phase: Phase 2/3
Start: Nov 1, 2018
Completion: Jun 1, 2021
NCT03396601
NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression
Phase: Phase 3
Start: Jun 25, 2019
Completion: Dec 31, 2024
NCT03396068
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
Start: Dec 1, 2019
NCT04843761
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
Role: Collaborator
Start: Apr 20, 2021
Completion: Nov 20, 2022
NCT06729606
Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
NCT04990466
Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.
Start: Sep 30, 2021
Completion: Feb 28, 2022
NCT03395392
NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
Start: May 12, 2022
Completion: Mar 30, 2024
NCT06128213
NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis
Start: Mar 31, 2024
Completion: Sep 30, 2024